Panel Recommends Against OTC Singulair Due To Off-Label Use Risk
This article was originally published in The Tan Sheet
Executive Summary
FDA’s Nonprescription Drug Advisory Committee votes against recommending approval after weighing the risks and benefits of switching Merck’s Singulair Allergy 10 mg montelukast sodium for allergy relief.